Abstract

18P Association of DNA methylation profiles with pathologic complete response in early triple-negative breast cancer patients receiving neoadjuvant chemoimmunotherapy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract PO1-27-07: Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative
Ana Gil-Torralvo ... Francisco Javier Salvador Bofill
Cancer Research | VOL. 84
Ana Gil-Torralvo, et. al.Ana Gil-Torralvo ... Francisco Javier Salvador Bofill
02 May 2024
‘Small’ randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: more harm than good?
H Bonnefoi
Annals of Oncology | VOL. 16
H BonnefoiH Bonnefoi
02 Aug 2005
Abstract PD11-08: Associations of baseline breast MRI metrics and immune infiltration with chemotherapy response in triple negative breast cancer
Bonny Chau ... Laura C Kennedy
Cancer Research | VOL. 82
Bonny Chau, et. al.Bonny Chau ... Laura C Kennedy
15 Feb 2022
Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer
N L Hu ... P Yuan
Zhonghua zhong liu za zhi [Chinese journal of oncology] | VOL. 45
N L Hu, et. al.N L Hu ... P Yuan
23 Nov 2023
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy – a retrospective and biomarker study
Fernanda Costa Svedman ... Suzanne Egyhazi Brage
Immuno-Oncology and Technology | VOL. -
Fernanda Costa Svedman, et. al.Fernanda Costa Svedman ... Suzanne Egyhazi Brage
01 May 2024
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial
Caroline Dive ... Kirellos S Abbas
Immuno-Oncology and Technology | VOL. 22
Caroline Dive, et. al.Caroline Dive ... Kirellos S Abbas
18 Mar 2024
Table of Contents
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 21
--
01 Mar 2024
View more papers